Gemcitabine (BioDeep_00000002173)

 

Secondary id: BioDeep_00001867676

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

化学式: C9H11F2N3O4 (263.0718)
中文名称: 吉西他滨
谱图信息: 最多检出来源 Homo sapiens(blood) 41.4%

分子结构信息

SMILES: C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F
InChI: InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1

描述信息

Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide).
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BC - Pyrimidine analogues
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2603
CONFIDENCE standard compound; INTERNAL_ID 2106
D009676 - Noxae > D000963 - Antimetabolites
D000970 - Antineoplastic Agents
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].

同义名列表

20 个代谢物同义名

4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer; Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer; 2-Deoxy-2,2-difluorocytidine-5-O-monophosphate; Gemcitabine, (D-threo-pentafuranosyl)-isomer; 3-Epi Gemcitabine (Gemcitabine Impurity); 2,2-Difluoro-2-deoxycytidine; 2-Deoxy-2,2-difluorocytidine; 2-Deoxy-2-difluorocytidine; gemcitabine hydrochloride; 2,2-Difluorodeoxycytidine; Gemcitabinum; Gemcitabina; Gemcitabine; 2,2-DFDC; DFdCyd; Gemzar; LY 188011; Gemcitabine



数据库引用编号

51 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

2 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(2)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 10 BRAF, CASP9, CDK1, CDKN2A, ERCC1, FNTA, MUC1, SMAD4, TNK1, VIM
Peripheral membrane protein 1 TNK1
Endoplasmic reticulum membrane 1 CDK1
Nucleus 11 BRAF, BRCA2, CASP9, CDK1, CDKN2A, ERCC1, MET, MKI67, MUC1, SMAD4, ZNF135
cytosol 8 BRAF, BRCA2, CASP9, CDK1, CDKN2A, FNTA, SMAD4, VIM
nuclear body 2 MET, MKI67
phagocytic vesicle 1 VIM
centrosome 3 BRCA2, CDK1, SMAD4
nucleoplasm 7 BRCA2, CDK1, CDKN2A, ERCC1, MET, MKI67, SMAD4
RNA polymerase II transcription regulator complex 1 SMAD4
Cell membrane 5 ABCC1, BRAF, MUC1, SLC29A1, VIM
Multi-pass membrane protein 2 ABCC1, SLC29A1
cell surface 1 MET
glutamatergic synapse 1 BRAF
lysosomal membrane 1 EGF
postsynapse 3 BRAF, MET, SLC29A1
Presynapse 2 BRAF, SLC29A1
plasma membrane 10 ABCC1, BRAF, BTC, EGF, FNTA, MET, MUC1, SLC29A1, TNK1, VIM
Membrane 10 ABCC1, BRCA2, BTC, CDK1, EGF, MET, MKI67, MUC1, SLC29A1, TNK1
apical plasma membrane 3 ABCC1, MUC1, SLC29A1
axon 1 VIM
basolateral plasma membrane 2 ABCC1, SLC29A1
extracellular exosome 5 ABCC1, CDK1, EGF, MUC1, VIM
extracellular space 5 BTC, CRP, CSF3, EGF, MUC1
lysosomal lumen 1 CSF3
mitochondrion 4 BRAF, CASP9, CDK1, CDKN2A
protein-containing complex 3 BRCA2, CASP9, CDKN2A
intracellular membrane-bounded organelle 1 BRAF
Single-pass type I membrane protein 1 MUC1
Secreted 2 CRP, CSF3
extracellular region 5 BTC, CRP, CSF3, EGF, MET
Single-pass membrane protein 1 MET
mitochondrial matrix 2 CDK1, CDKN2A
transcription regulator complex 1 SMAD4
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 2 BRCA2, CDK1
nucleolus 2 CDKN2A, MKI67
midbody 1 CDK1
vesicle 1 MUC1
Apical cell membrane 2 MUC1, SLC29A1
Cytoplasm, cytoskeleton 1 VIM
focal adhesion 1 VIM
Peroxisome 1 VIM
secretory granule 1 BRCA2
intermediate filament 1 VIM
lateral plasma membrane 2 ABCC1, SLC29A1
receptor complex 1 MET
neuron projection 2 BRAF, VIM
chromatin 2 MUC1, SMAD4
cell leading edge 1 VIM
microtubule associated complex 1 FNTA
mitotic spindle 1 CDK1
Chromosome 1 MKI67
cytoskeleton 1 VIM
[Isoform 3]: Nucleus 1 ERCC1
Nucleus, nucleolus 2 CDKN2A, MKI67
chromosome, telomeric region 3 BRCA2, CDK1, ERCC1
Basolateral cell membrane 1 SLC29A1
microtubule organizing center 1 VIM
lateral element 1 BRCA2
Nucleus, nucleoplasm 1 CDKN2A
cell body 1 BRAF
intermediate filament cytoskeleton 1 VIM
basal plasma membrane 2 ABCC1, MET
Golgi lumen 1 MUC1
nuclear matrix 1 VIM
platelet alpha granule lumen 1 EGF
Nucleus matrix 1 VIM
apoptosome 1 CASP9
[Isoform 2]: Cytoplasm 1 ERCC1
clathrin-coated endocytic vesicle membrane 2 BTC, EGF
[Isoform 1]: Nucleus 1 ERCC1
heteromeric SMAD protein complex 1 SMAD4
SMAD protein complex 1 SMAD4
spindle microtubule 1 CDK1
DNA repair complex 1 BRCA2
activin responsive factor complex 1 SMAD4
[Isoform 4]: Nucleus 1 ERCC1
cyclin-dependent protein kinase holoenzyme complex 1 CDK1
endocytic vesicle lumen 1 CSF3
cyclin A1-CDK1 complex 1 CDK1
cyclin A2-CDK1 complex 1 CDK1
cyclin B1-CDK1 complex 1 CDK1
ERCC4-ERCC1 complex 1 ERCC1
nucleotide-excision repair complex 1 ERCC1
nucleotide-excision repair factor 1 complex 1 ERCC1
senescence-associated heterochromatin focus 1 CDKN2A
nuclear ubiquitin ligase complex 1 BRCA2
CAAX-protein geranylgeranyltransferase complex 1 FNTA
protein farnesyltransferase complex 1 FNTA
BRCA2-MAGE-D1 complex 1 BRCA2
caspase complex 1 CASP9
[Isoform smARF]: Mitochondrion 1 CDKN2A


文献列表

  • Qiqi Wang, Mengyuan Gong, Rujuan Liu, Jiantao Mo, Ruiping Bai, Rui An, Xueni Wang, Liang Han, Zheng Wang, Qingyong Ma, Zheng Wu, Cancan Zhou. Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024 Jul; 129(?):155656. doi: 10.1016/j.phymed.2024.155656. [PMID: 38723529]
  • Binbin Luo, Linyi Song, Limiao Chen, Yue Cai, Mingwei Zhang, Shenyi Wang. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024 Jul; 129(?):155675. doi: 10.1016/j.phymed.2024.155675. [PMID: 38678954]
  • Su-Li Zhu, Ming Qi, Mei-Ting Chen, Jia-Peng Lin, Hai-Fu Huang, Li-Juan Deng, Xing-Wang Zhou. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024 Jun; 128(?):155377. doi: 10.1016/j.phymed.2024.155377. [PMID: 38503154]
  • Sofia Sturm, Günter Niegisch, Joachim Windolf, Christoph V Suschek. Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine. International journal of molecular sciences. 2024 Apr; 25(9):. doi: 10.3390/ijms25094868. [PMID: 38732087]
  • Huan Tang, Xin Miao, Cheng Yu, Changpeng Chai, Yuanhui Su, Lu Li, Jianfeng Yi, Zhenzhen Ye, Long Miao, Zhengfeng Wang, Hui Zhang, Hao Xu, Wence Zhou. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. Scientific reports. 2024 04; 14(1):9259. doi: 10.1038/s41598-024-56464-w. [PMID: 38649719]
  • Shihe Hu, Cuihua Jiang, Qiaomei Jin. Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy. European journal of medicinal chemistry. 2024 Apr; 269(?):116351. doi: 10.1016/j.ejmech.2024.116351. [PMID: 38547734]
  • Akane Suda, Banlanjo Abdulaziz Umaru, Yui Yamamoto, Hiroki Shima, Yuriko Saiki, Yijun Pan, Liang Jin, Jiaqi Sun, Yi Ling Clare Low, Chitose Suzuki, Takaaki Abe, Kazuhiko Igarashi, Toru Furukawa, Yuji Owada, Yoshiteru Kagawa. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth. Scientific reports. 2024 02; 14(1):4409. doi: 10.1038/s41598-024-55050-4. [PMID: 38388563]
  • Jingcheng Zhang, Yutong Wang, Lejunzi Wang, Lei You, Taiping Zhang. Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment. Chinese medical journal. 2024 Feb; 137(4):408-420. doi: 10.1097/cm9.0000000000002758. [PMID: 37545027]
  • Dan Liu, Linjiang Wang, Henan Li, Dong Li, Jianwen Zhou, Jing Wang, Qi Zhang, Defu Cai. Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma. Molecules (Basel, Switzerland). 2024 Jan; 29(3):. doi: 10.3390/molecules29030675. [PMID: 38338418]
  • Abudureyimu Tuerhong, Jin Xu, Wei Wang, Si Shi, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Xianjun Yu, Chen Liang. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Surgery. 2024 Jan; ?(?):. doi: 10.1016/j.surg.2023.12.019. [PMID: 38302326]
  • Lijie Zhou, Kaixuan Du, Yiheng Dai, Youmiao Zeng, Yongbo Luo, Mengda Ren, Wenbang Pan, Yuanhao Liu, Lailai Zhang, Ronghui Zhu, Dapeng Feng, Fengyan Tian, Chaohui Gu. Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer. Journal of translational medicine. 2024 Jan; 22(1):55. doi: 10.1186/s12967-024-04867-8. [PMID: 38218866]
  • Xiaowei Wang, Hongwei Lu, Fang Luo, Dan Wang, Apeng Wang, Xuelei Wang, Wenkai Feng, Xiaobo Wang, Jiayi Su, Mingliang Liu, Guimin Xia. Lipid-like gemcitabine diester-loaded liposomes for improved chemotherapy of pancreatic cancer. Journal of controlled release : official journal of the Controlled Release Society. 2024 Jan; 365(?):112-131. doi: 10.1016/j.jconrel.2023.11.028. [PMID: 37981050]
  • Ji He, Piyush Bugde, Jiawei Li, Riya Biswas, Siting Li, Xuewei Yang, Fang Tian, Zimei Wu, Yan Li. Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca‑2 and PANC‑1 cells. Oncology reports. 2024 Jan; 51(1):. doi: 10.3892/or.2023.8666. [PMID: 37975256]
  • Negar Nasri, Shaghayegh Saharkhiz, Ghasem Dini, Saghar Yousefnia. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer. International journal of pharmaceutics. 2023 Dec; 648(?):123606. doi: 10.1016/j.ijpharm.2023.123606. [PMID: 37972671]
  • Xin Xu, Xi-Yang Sun, Ming Chang, Zhao-Liang Hu, Ting-Ting Cheng, Tai-Jun Hang, Min Song. Gemcitabine enhances pharmacokinetic exposure of the major components of Danggui Buxue Decoction in rat via the promotion of intestinal permeability and down-regulation of CYP3A for combination treatment of non-small cell lung cancer. Pharmaceutical biology. 2023 Dec; 61(1):1298-1309. doi: 10.1080/13880209.2023.2246500. [PMID: 37606265]
  • Momoko Gyoten, Yi Luo, Rina Fujiwara-Tani, Shiori Mori, Ruiko Ogata, Shingo Kishi, Hiroki Kuniyasu. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. International journal of molecular sciences. 2023 Nov; 24(23):. doi: 10.3390/ijms242316814. [PMID: 38069135]
  • Lijie Han, Yongsheng Jiang, Minmin Shi, Lina Gan, Zhichong Wu, Meilin Xue, Youwei Zhu, Cheng Xiong, Ting Wang, Xiaozhu Lin, Baiyong Shen, Lingxi Jiang, Hao Chen. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Journal of translational medicine. 2023 Nov; 21(1):838. doi: 10.1186/s12967-023-04702-6. [PMID: 37990271]
  • Shukui Qin, Jin Li, Yuxian Bai, Zishu Wang, Zhendong Chen, Ruihua Xu, Jianming Xu, Hongmei Zhang, Jia Chen, Ying Yuan, Tianshu Liu, Lin Yang, Haijun Zhong, Donghui Chen, Lin Shen, Chunyi Hao, Deliang Fu, Ying Cheng, Jianwei Yang, Qiong Wang, Baoli Qin, Hongming Pan, Jun Zhang, Xianhong Bai, Qingshan Zheng. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Nov; 41(33):5163-5173. doi: 10.1200/jco.22.02630. [PMID: 37647576]
  • Haihong Cheng, Yuxin Sun, Xiaopeng Yu, Di Zhou, Jun Ding, Shouhua Wang, Fei Ma. FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling. Drug discoveries & therapeutics. 2023 Nov; 17(5):328-339. doi: 10.5582/ddt.2023.01036. [PMID: 37743521]
  • Xuena Dong, Yuhan Wang, Shuhui Wang, Cong Li, Min Zhang, Fanglin Hou. Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors. Archivos espanoles de urologia. 2023 Nov; 76(9):657-665. doi: 10.56434/j.arch.esp.urol.20237609.80. [PMID: 38053420]
  • Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar. Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer. Pharmaceutical patent analyst. 2023 Nov; 12(6):261-273. doi: 10.4155/ppa-2023-0024. [PMID: 38214201]
  • Myeong Jin Kim, Hyung Sun Kim, Hyeon Woong Kang, Da Eun Lee, Woosol Chris Hong, Ju Hyun Kim, Minsoo Kim, Jae-Ho Cheong, Hyo Jung Kim, Joon Seong Park. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cells. 2023 10; 12(20):. doi: 10.3390/cells12202509. [PMID: 37887353]
  • Marutpong Detarya, Panupong Mahalapbutr, Orawan Waenphimai, Sonexai Kidoikhammouan, Somkid Janeklang, Kanlayanee Sawanyawisuth, Kulthida Vaeteewoottacharn, Wunchana Seubwai, Charupong Saengboonmee, Teerawut Thothaisong, Wachirachai Pabuprapap, Apichart Suksamrarn, Sopit Wongkham. Induction of apoptotic cell death of cholangiocarcinoma cells by tiliacorinine from Tiliacora triandra: A mechanistic insight. Biochimica et biophysica acta. General subjects. 2023 Oct; 1867(12):130486. doi: 10.1016/j.bbagen.2023.130486. [PMID: 37813201]
  • Kyle D G Saunders, Johanna von Gerichten, Holly-May Lewis, Priyanka Gupta, Matt Spick, Catia Costa, Eirini Velliou, Melanie J Bailey. Single-Cell Lipidomics Using Analytical Flow LC-MS Characterizes the Response to Chemotherapy in Cultured Pancreatic Cancer Cells. Analytical chemistry. 2023 10; 95(39):14727-14735. doi: 10.1021/acs.analchem.3c02854. [PMID: 37725657]
  • Claire Gazaille, Elia Bozzato, Neda Madadian-Bozorg, Adélie Mellinger, Marion Sicot, Umer Farooq, Patrick Saulnier, Joël Eyer, Véronique Préat, Nicolas Bertrand, Guillaume Bastiat. Glioblastoma-targeted, local and sustained drug delivery system based on an unconventional lipid nanocapsule hydrogel. Biomaterials advances. 2023 Oct; 153(?):213549. doi: 10.1016/j.bioadv.2023.213549. [PMID: 37453243]
  • Epiphane K Silli, Mengfei Li, Yuting Shao, Yiran Zhang, Guilin Hou, Jiaqian Du, Jingdan Liang, Ying Wang. Liposomal Nanostructures for Gemcitabine and Paclitaxel Delivery in Pancreatic Cancer. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2023 Sep; ?(?):. doi: 10.1016/j.ejpb.2023.09.014. [PMID: 37758121]
  • Wanhui Wei, Yuanyuan Lu, Qian Hu, Jinwen Yin, Youwei Wang, Heng Zhang, Qiu Zhao, Lan Liu. Synergistic antitumor efficacy of gemcitabine and cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via Sp1-SAT1-polyamine metabolism pathway. Cellular oncology (Dordrecht). 2023 Sep; ?(?):. doi: 10.1007/s13402-023-00870-1. [PMID: 37684512]
  • Yan Shan Loo, N Idayu Zahid, Thiagarajan Madheswaran, Shinya Ikeno, Armania Nurdin, Intan Diana Mat Azmi. Coencapsulation of Gemcitabine and Thymoquinone in Citrem-Phosphatidylcholine Hexosome Nanocarriers Improves In Vitro Cellular Uptake in Breast Cancer Cells. Molecular pharmaceutics. 2023 09; 20(9):4611-4628. doi: 10.1021/acs.molpharmaceut.3c00333. [PMID: 37587099]
  • Yuhan Yang, Haitao Gu, Kundong Zhang, Zengya Guo, Xiaofeng Wang, Qingyun Wei, Ling Weng, Xuan Han, Yan Lv, Meng Cao, Peng Cao, Chen Huang, Zhengjun Qiu. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. BMC cancer. 2023 Aug; 23(1):789. doi: 10.1186/s12885-023-11239-w. [PMID: 37612627]
  • Chih-Hao Chiu, Yu-Jung Lin, Samiraj Ramesh, Wei-Wen Kuo, Ming-Cheng Chen, Chia-Hua Kuo, Chi-Cheng Li, Tso-Fu Wang, Yueh-Min Lin, Po-Hsiang Liao, Chih-Yang Huang. Gemcitabine resistance in non-small cell lung cancer is mediated through activation of the PI3K/AKT/NF-κB pathway and suppression of ERK signaling by reactive oxygen species. Journal of biochemical and molecular toxicology. 2023 Aug; ?(?):e23497. doi: 10.1002/jbt.23497. [PMID: 37564025]
  • Hui He, Jiaqi Guo, Yunxiang Hu, Han Zhang, Xinyang Li, Jian Zhang, Shi Jin. Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling. Acta biochimica et biophysica Sinica. 2023 Jul; ?(?):. doi: 10.3724/abbs.2023040. [PMID: 37489008]
  • Chi-Cheng Li, Cheng-You Lu, Chiung-Hung Hsu, Dennis Jine-Yuan Hsieh, Tso-Fu Wang, Tsung-Jung Ho, Wei-Wen Kuo, Cecilia Hsuan Day, Shih-Chieh Liao, Ming-Cheng Chen, Chih-Yang Huang. Calycosin inhibits gemcitabine-resistant lung cancer cells proliferation through modulation of the LDOC1/GNL3L/NFκB. The Chinese journal of physiology. 2023 Jul; 66(4):189-199. doi: 10.4103/cjop.cjop-d-23-00009. [PMID: 37635478]
  • Andriana Inkoom, Nkafu Bechem Ndemazie, Taylor Smith, Esther Frimpong, Raviteja Bulusu, Rosemary Poku, Xue Zhu, Bo Han, Jose Trevino, Edward Agyare. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC cancer. 2023 May; 23(1):435. doi: 10.1186/s12885-023-10928-w. [PMID: 37179357]
  • Ran Qi, Yixuan Bai, Kun Li, Nanbin Liu, Yan Xu, Emre Dal, Yufeng Wang, Rui Lin, Hui Wang, Zhongyan Liu, Xinbo Li, Xiuyan Wang, Baomin Shi. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2023 Mar; 68(?):100960. doi: 10.1016/j.drup.2023.100960. [PMID: 37003125]
  • Li Tao, Kehui Zhou, Yang Zhao, Xiangyu Xia, Yajie Guo, Yang Gao, Guoping Peng, Yanqing Liu. Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation. Journal of ethnopharmacology. 2023 Feb; ?(?):116295. doi: 10.1016/j.jep.2023.116295. [PMID: 36813244]
  • Frédéric Lirussi, Kyrylo Pyrshev, Semen Yesylevskyy, Timothée Rivel, Tatiana Lopez, Eleonore Coppens, Simona Mura, Patrick Couvreur, Christophe Ramseyer. Plasma membrane lipid bilayer is druggable: Selective delivery of gemcitabine-squalene nano-medicine to cancer cells. Biochimica et biophysica acta. Molecular basis of disease. 2023 02; 1869(2):166614. doi: 10.1016/j.bbadis.2022.166614. [PMID: 36494037]
  • Xinxin Zeng, Liyue Sun, Xiaomei Ling, Yuying Jiang, Ju Shen, Lei Liang, Xuhui Zhang. Comprehensive analysis identifies novel targets of gemcitabine to improve chemotherapy treatment strategies for colorectal cancer. Frontiers in endocrinology. 2023; 14(?):1170526. doi: 10.3389/fendo.2023.1170526. [PMID: 37664836]
  • Noelia González-Ballesteros, Immacolata Maietta, Raquel Rey-Méndez, M Carmen Rodríguez-Argüelles, Mariano Lastra-Valdor, Antonella Cavazza, Maria Grimaldi, Franca Bigi, Rosana Simón-Vázquez. Gold Nanoparticles Synthesized by an Aqueous Extract of Codium tomentosum as Potential Antitumoral Enhancers of Gemcitabine. Marine drugs. 2022 Dec; 21(1):. doi: 10.3390/md21010020. [PMID: 36662193]
  • Shruti Gupta, Hemanth Naick Banavath, Kiran Kumar Tejavath. Pharmacoinformatic screening of phytoconstituent and evaluation of its anti-PDAC effect using in vitro studies. Journal of biomolecular structure & dynamics. 2022 Dec; ?(?):1-15. doi: 10.1080/07391102.2022.2155701. [PMID: 36510680]
  • San-Hua Su, Navaneethan Sundhar, Wei-Wen Kuo, Shang-Chih Lai, Chia-Hua Kuo, Tsung-Jung Ho, Pi-Yu Lin, Shinn-Zong Lin, Cheng Yen Shih, Yu-Jung Lin, Chih-Yang Huang. Artemisia argyi extract induces apoptosis in human gemcitabine-resistant lung cancer cells via the PI3K/MAPK signaling pathway. Journal of ethnopharmacology. 2022 Dec; 299(?):115658. doi: 10.1016/j.jep.2022.115658. [PMID: 36075273]
  • Tingting Luo, Luhua Bai, Yi Zhang, Leidan Huang, Hui Li, Shunji Gao, Xiaoxiao Dong, Ningshan Li, Zheng Liu. Optimal treatment occasion for ultrasound stimulated microbubbles in promoting gemcitabine delivery to VX2 tumors. Drug delivery. 2022 Dec; 29(1):2796-2804. doi: 10.1080/10717544.2022.2115163. [PMID: 36047064]
  • Marie Moussouni, Véronique Graff, Franck Couturier, Hugo Herrscher. Drug interactions causing warfarin overdose in a patient with a pancreatic cancer : a case report. Chemotherapy. 2022 Nov; ?(?):. doi: 10.1159/000528063. [PMID: 36446317]
  • Yi-Dan Zheng, Li-Mei Ma, Jin-Jian Lu, Tian Chai, Mohammad Reza Naghavi, Jun-Yi Ma, Chun-Yan Sang, Jun-Li Yang. Nardoguaianone L Isolated from Nardostachys jatamansi Improved the Effect of Gemcitabine Chemotherapy via Regulating AGE Signaling Pathway in SW1990 Cells. Molecules (Basel, Switzerland). 2022 Oct; 27(20):. doi: 10.3390/molecules27206849. [PMID: 36296442]
  • Lakshmi Tunki, Parimala Devi Ganthala, Deep Pooja, Sai Balaji Andugulapati, Hitesh Kulhari, Ramakrishna Sistla, Suresh Kumar Bhargava. Ameliorating the antitumor activity of gemcitabine against breast tumor using αvβ3 integrin-targeting lipid nanoparticles. Drug development and industrial pharmacy. 2022 Aug; 48(8):384-396. doi: 10.1080/03639045.2022.2120492. [PMID: 36047536]
  • Ashwaq A Al-Mutairi, Mayson H Alkhatib. Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells. Journal of microencapsulation. 2022 Aug; 39(5):467-480. doi: 10.1080/02652048.2022.2109218. [PMID: 35916335]
  • Taro Horino, Satoshi Inotani, Masayuki Ishihara, Yoshio Terada. Gemcitabine-induced renal thrombotic microangiopathy. Nephrology (Carlton, Vic.). 2022 08; 27(8):724-725. doi: 10.1111/nep.14043. [PMID: 35429056]
  • Siamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, Gary D Steinberg, Manju Aron, Christopher J Cutie, Kirk A Keegan, John C Maffeo, Donald L Reynolds, Bradley Raybold, Albert Chau, J Alfred Witjes. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. Urologic oncology. 2022 07; 40(7):344.e1-344.e9. doi: 10.1016/j.urolonc.2022.02.009. [PMID: 35431132]
  • Concetta Panebianco, Annacandida Villani, Federica Pisati, Fabrizio Orsenigo, Marynka Ulaszewska, Tiziana Pia Latiano, Adele Potenza, Annapaola Andolfo, Fulvia Terracciano, Claudio Tripodo, Francesco Perri, Valerio Pazienza. Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Jul; 151(?):113163. doi: 10.1016/j.biopha.2022.113163. [PMID: 35617803]
  • Lin Zhu, Rui Chen, Qianyu Yang, Hongxia Liu, Qingshan Zheng, Lujin Li. Modelling an evaluation of the efficacy and safety of gemcitabine combined with platinum in the treatment of non-small cell lung cancer. Journal of clinical pharmacy and therapeutics. 2022 Jul; 47(7):986-994. doi: 10.1111/jcpt.13632. [PMID: 35246996]
  • Jia Huo, Lijun Fu, Mengyuan Jin, Zhaoming Li, Mingzhi Zhang. IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4. Investigational new drugs. 2022 06; 40(3):537-545. doi: 10.1007/s10637-022-01224-8. [PMID: 35226228]
  • Goro Ueno, Yoshifumi Iwagami, Shogo Kobayashi, Suguru Mitsufuji, Daisaku Yamada, Yoshito Tomimaru, Hirofumi Akita, Tadafumi Asaoka, Takehiro Noda, Kunihito Gotoh, Masaki Mori, Yuichiro Doki, Hidetoshi Eguchi. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer. Annals of surgical oncology. 2022 May; 29(5):2899-2909. doi: 10.1245/s10434-021-11152-1. [PMID: 34994902]
  • Seung Soo Hong, Sena Lee, Sung Hwan Lee, Seonhowa Kim, Doyoung Kim, Hanseul Park, Jongook Lee, Jung Hwan Lee, Chang Moo Kang. Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models. Cancer science. 2022 May; 113(5):1752-1762. doi: 10.1111/cas.15318. [PMID: 35243724]
  • Juan Zhang, Hong-Xi Xu, William Chi Shing Cho, Wah Cheuk, Yang Li, Qiong-Hui Huang, Wen Yang, Yan-Fang Xian, Zhi-Xiu Lin. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Journal of experimental & clinical cancer research : CR. 2022 Mar; 41(1):90. doi: 10.1186/s13046-022-02270-z. [PMID: 35272669]
  • Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia Del Pozo, Jaime Martínez de Villarreal, Francisco X Real, Noemí Vidal, Gabriel Capella, Ramon Alemany, Emma Blasi, Carmen Blasco, Manel Cascalló, Ramon Salazar. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. Journal for immunotherapy of cancer. 2022 03; 10(3):. doi: 10.1136/jitc-2021-003255. [PMID: 35338084]
  • Yangyang Guo, Hengyue Zhu, Yanyi Xiao, Hangcheng Guo, Miaomiao Lin, Ziwei Yuan, Xuejia Yang, Youze Huang, Qiyu Zhang, Yongheng Bai. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell death & disease. 2022 02; 13(2):112. doi: 10.1038/s41419-022-04573-7. [PMID: 35115509]
  • Jochen Rutz, Sebastian Maxeiner, Eva Juengel, Felix K-H Chun, Igor Tsaur, Roman A Blaheta. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. Nutrients. 2022 Jan; 14(2):. doi: 10.3390/nu14020369. [PMID: 35057550]
  • Theodora Chatzisideri, George Leonidis, Theodoros Karampelas, Eleni Skavatsou, Angeliki Velentza-Almpani, Francesca Bianchini, Constantin Tamvakopoulos, Vasiliki Sarli. Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine. Journal of medicinal chemistry. 2022 01; 65(1):271-284. doi: 10.1021/acs.jmedchem.1c01468. [PMID: 34967607]
  • Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC cancer. 2022 Jan; 22(1):19. doi: 10.1186/s12885-021-09139-y. [PMID: 34980029]
  • Shuxia Han, Qing Liu, ZhiJuan Yang, JingWen Ma, Dan Liu, Caiping Yan, Duoxian Liang. Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma. Disease markers. 2022; 2022(?):6400227. doi: 10.1155/2022/6400227. [PMID: 35069934]
  • Hirotaka Kashima, Ryuki Minami, Tomomi Ozawa, Atsushi Matsumoto, Yuto Kimura, Yasuhiro Takeda, Taro Ueo, Akihiro Okano, Fusako Kusumi, Masaya Ohana. [A case of thrombotic microangiopathy during chemotherapy with gemcitabine in a patient with pancreatic cancer]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 2022; 119(3):259-266. doi: 10.11405/nisshoshi.119.259. [PMID: 35264490]
  • Shatha Abd Al-Jabbar, Vesen Atiroğlu, Rana M Hameed, Gamze Guney Eskiler, Atheer Atiroğlu, Asuman Deveci Ozkan, Mahmut Özacar. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells. Bioorganic chemistry. 2022 01; 118(?):105467. doi: 10.1016/j.bioorg.2021.105467. [PMID: 34781115]
  • Jie Zhang, Yueyin Pan, Qin Shi, Guojun Zhang, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, Aimin Zang, Qisen Guo, Guangqiang Zhao, Ziping Wang, Jianxing He, Wenxiu Yao, Xiaohong Wu, Kai Chen, Xiaohua Hu, Chunhong Hu, Lu Yue, Da Jiang, Guangfa Wang, Junfeng Liu, Guohua Yu, Junling Li, Jianling Bai, Wenmin Xie, Weihong Zhao, Lihong Wu, Caicun Zhou. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. Cancer communications (London, England). 2022 01; 42(1):3-16. doi: 10.1002/cac2.12225. [PMID: 34699693]
  • Christos Fountzilas, Alex Adjei, Mateusz Opyrchal, Rachel Evans, Mohammad Ghasemi, Kristopher Attwood, Adrienne Groman, Wiam Bshara, Andrew Goey, John Wilton, Wen Wee Ma, Renuka Iyer. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. International journal of cancer. 2021 12; 149(12):2063-2074. doi: 10.1002/ijc.33754. [PMID: 34319586]
  • Cui Zhou, Wenchong Ye, Yongjun Cao, Meizhu Wang, Dongxia Qi, Guohao Liao, Houkai Li, Weiping Huang, Wenming Chen, Xiaoyang Wang, Wen Zhou. A gulose moiety contributes to the belomycin (BLM) disaccharide selective targeting to lung cancer cells. European journal of medicinal chemistry. 2021 Dec; 226(?):113866. doi: 10.1016/j.ejmech.2021.113866. [PMID: 34619466]
  • Abigail Ferreira, Rui Lapa, Nuno Vale. Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration. Current issues in molecular biology. 2021 Dec; 43(3):2189-2198. doi: 10.3390/cimb43030153. [PMID: 34940127]
  • Zahra Shekarbeygi, Changiz Karami, Esmaeil Esmaeili, Sajad Moradi, Mohsen Shahlaei. Development of Ag nanoparticle-carbon quantum dot nanocomplex as fluorescence sensor for determination of gemcitabine. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2021 Dec; 262(?):120148. doi: 10.1016/j.saa.2021.120148. [PMID: 34247037]
  • Ashwaq H S Yehya, Muhammad Asif, Amin M S Abdul Majid, Chern E Oon. Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer. Biomedical journal. 2021 12; 44(6):694-708. doi: 10.1016/j.bj.2020.05.015. [PMID: 35166208]
  • Nathaniel R Wilson, Andrew J Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Pheroze Tamboli, Amishi Y Shah, Giannicola Genovese, Jose A Karam, Christopher G Wood, Nizar M Tannir, Pavlos Msaouel. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clinical genitourinary cancer. 2021 12; 19(6):e401-e408. doi: 10.1016/j.clgc.2021.08.007. [PMID: 34625389]
  • Fumihiro Nishimura, Tomoko Ushijima, Shinsuke Hamada, Daisuke Kadowaki, Shigeyuki Miyamura, Kentaro Oniki, Junji Saruwatari. Evaluation of renal function using cystatin C-based estimated glomerular filtration rate in patients with urothelial carcinoma treated with gemcitabine and cisplatin chemotherapy. Journal of clinical pharmacy and therapeutics. 2021 Dec; 46(6):1622-1628. doi: 10.1111/jcpt.13501. [PMID: 34339546]
  • Eleonore Coppens, Didier Desmaële, Timothée Naret, Sébastien Garcia-Argote, Sophie Feuillastre, Grégory Pieters, Catherine Cailleau, Jean-Louis Paul, Bastien Prost, Audrey Solgadi, Jean-Philippe Michel, Magali Noiray, Patrick Couvreur, Simona Mura. Gemcitabine lipid prodrug nanoparticles: Switching the lipid moiety and changing the fate in the bloodstream. International journal of pharmaceutics. 2021 Nov; 609(?):121076. doi: 10.1016/j.ijpharm.2021.121076. [PMID: 34481886]
  • Ling Zhou, Chen Yang, Weilan Zhong, Qiaoyun Wang, Daolai Zhang, Jiayu Zhang, Shuyang Xie, Maolei Xu. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. Biochemical pharmacology. 2021 11; 193(?):114813. doi: 10.1016/j.bcp.2021.114813. [PMID: 34673014]
  • Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, Berta Laquente, Rafael Álvarez, Ana Mato-Berciano, Marta Gimenez-Alejandre, Sara Morgado, Alba Rodríguez-García, Maria V Maliandi, M Carmen Riesco, Rafael Moreno, Mireia M Ginestà, Mercedes Perez-Carreras, Joan B Gornals, Susana Prados, Sofía Perea, Gabriel Capella, Ramon Alemany, Ramon Salazar, Emma Blasi, Carmen Blasco, Manel Cascallo, Manuel Hidalgo. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Journal for immunotherapy of cancer. 2021 11; 9(11):. doi: 10.1136/jitc-2021-003254. [PMID: 35149591]
  • Jianhui Yang, Jin Xu, Bo Zhang, Zhen Tan, Qingcai Meng, Jie Hua, Jiang Liu, Wei Wang, Si Shi, Xianjun Yu, Chen Liang. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. International journal of molecular sciences. 2021 Oct; 22(20):. doi: 10.3390/ijms222010944. [PMID: 34681603]
  • Ryotaro Matsumoto, Shin Hamada, Yu Tanaka, Keiko Taguchi, Masayuki Yamamoto, Atsushi Masamune. Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression. The Journal of pharmacology and experimental therapeutics. 2021 10; 379(1):33-40. doi: 10.1124/jpet.121.000744. [PMID: 34321315]
  • Samer S AlMasri, Mazen S Zenati, Annissa Desilva, Ibrahim Nassour, Brian A Boone, Aatur D Singhi, David L Bartlett, Lance A Liotta, Virginia Espina, Patricia Loughran, Michael T Lotze, Alessandro Paniccia, Herbert J Zeh, Amer H Zureikat, Nathan Bahary. Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. Cancer medicine. 2021 10; 10(20):7233-7241. doi: 10.1002/cam4.4211. [PMID: 34559451]
  • Hyung-Don Kim, Hyeon-Su Im, Jwa Hoon Kim, Hyehyun Jeong, Shin Kyo Yoon, Inkeun Park, Jae Lyun Lee. Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. Cancer research and treatment. 2021 Oct; 53(4):1166-1173. doi: 10.4143/crt.2021.091. [PMID: 33677847]
  • Hongzhe Shi, Wen Zhang, Xingang Bi, Dong Wang, Zejun Xiao, Youyan Guan, Kaopeng Guan, Jun Tian, Hongsong Bai, Linjun Hu, Chuanzhen Cao, Weixing Jiang, Zhilong Hu, Jin Zhang, Yan Chen, Shan Zheng, Xiaoli Feng, Changling Li, Yexiong Li, Jianhui Ma, Yueping Liu, Aiping Zhou, Jianzhong Shou. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Cancer research and treatment. 2021 Oct; 53(4):1156-1165. doi: 10.4143/crt.2020.1356. [PMID: 33592141]
  • Zi-Yang Chan, Premanand Krishnan, Sayed Mohammadhossein Modaresi, Ling-Wei Hii, Chun-Wai Mai, Wei-Meng Lim, Chee-Onn Leong, Yun-Yee Low, Soon-Kit Wong, Kien-Thai Yong, Alyssa Zi-Xin Leong, Mei-Kee Lee, Kang-Nee Ting, Kuan-Hon Lim. Monomeric, Dimeric, and Trimeric Tropane Alkaloids from Pellacalyx saccardianus. Journal of natural products. 2021 08; 84(8):2272-2281. doi: 10.1021/acs.jnatprod.1c00374. [PMID: 34342431]
  • Lei Wang, Rongrong Bi, Lei Li, Kun Zhou, Hang Yin. lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy. Aging. 2021 08; 13(15):19272-19281. doi: 10.18632/aging.203251. [PMID: 34374662]
  • Keiran A Logan, Heather Nesbitt, Bridgeen Callan, Jinhui Gao, Thomas McKaig, Mark Taylor, Mark Love, Anthony P McHale, John F Callan. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2021 Aug; 165(?):374-382. doi: 10.1016/j.ejpb.2021.05.018. [PMID: 34038797]
  • Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC nephrology. 2021 07; 22(1):267. doi: 10.1186/s12882-021-02470-3. [PMID: 34284729]
  • L Gao, T Shao, W Zheng, J Ding. Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2021 Jul; 23(7):1386-1393. doi: 10.1007/s12094-020-02531-3. [PMID: 33566305]
  • Hongtao Xu, Yan Li, James W Paxton, Zimei Wu. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine. Pharmaceutical research. 2021 Jul; 38(7):1209-1219. doi: 10.1007/s11095-021-03072-2. [PMID: 34189639]
  • Jason M Farrow, Sean Q Kern, Gustavo M Gryzinski, Chandru P Sundaram. Nephron-sparing management of upper tract urothelial carcinoma. Investigative and clinical urology. 2021 07; 62(4):389-398. doi: 10.4111/icu.20210113. [PMID: 34190434]
  • Makoto Ueno, Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Tomoko Kataoka, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Tomohisa Yamamoto, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Atsushi Miyamoto, Hironori Yamaguchi, Tomohiro Nishina, Hirofumi Shirakawa, Yasushi Kojima, Takamasa Oono, Yasuyuki Kawamoto, Masayuki Furukawa, Tomohisa Iwai, Kentaro Sudo, Hiroyuki Miyakawa, Tatsuya Yamashita, Ichirou Yasuda, Hidenori Takahashi, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. Scientific reports. 2021 06; 11(1):12885. doi: 10.1038/s41598-021-92166-3. [PMID: 34145336]
  • Yan Liu, Ming Chang, Zhaoliang Hu, Xin Xu, Wei Wu, Manru Ning, Taijun Hang, Min Song. Danggui Buxue Decoction enhances the anticancer activity of gemcitabine and alleviates gemcitabine-induced myelosuppression. Journal of ethnopharmacology. 2021 Jun; 273(?):113965. doi: 10.1016/j.jep.2021.113965. [PMID: 33639205]
  • Mingtan Tang, Lina Lozano Hernandez, Joy N Reginald-Opara, Darren Svirskis, Euphemia Leung, Hongbo Wang, Zimei Wu. Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery. International journal of pharmaceutics. 2021 Jun; 602(?):120659. doi: 10.1016/j.ijpharm.2021.120659. [PMID: 33933647]
  • Jia-Ling Ruan, Richard J Browning, Yesna O Yildiz, Luca Bau, Sukanta Kamila, Michael D Gray, Lisa Folkes, Alix Hampson, Anthony P McHale, John F Callan, Borivoj Vojnovic, Anne E Kiltie, Eleanor Stride. Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles. Ultrasound in medicine & biology. 2021 06; 47(6):1596-1615. doi: 10.1016/j.ultrasmedbio.2021.02.001. [PMID: 33707089]
  • Takeshi Matsumoto, Takashi Komori, Yuta Yoshino, Tadaaki Ioroi, Tsukasa Kitahashi, Hiromu Kitahara, Kohei Ono, Tamami Higuchi, Masayo Sakabe, Hiroshi Kori, Masahiro Kano, Ritsuko Hori, Yukio Kato, Shinji Hagiwara. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models. Pharmaceutical research. 2021 Jun; 38(6):1093-1106. doi: 10.1007/s11095-021-03045-5. [PMID: 33961188]
  • Inken Salewski, Julia Henne, Leonie Engster, Bjoern Schneider, Heiko Lemcke, Anna Skorska, Peggy Berlin, Larissa Henze, Christian Junghanss, Claudia Maletzki. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. International journal of molecular sciences. 2021 Jun; 22(11):. doi: 10.3390/ijms22115990. [PMID: 34206051]
  • Masashi Nishikubo, Yoshimitsu Shimomura, Nobuhiro Hiramoto, Naohiko Sawamura, Takako Yamaguchi, Shigeo Hara, Takayuki Ishikawa. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. BMC nephrology. 2021 05; 22(1):175. doi: 10.1186/s12882-021-02386-y. [PMID: 33980166]
  • Bo Zhong, Elizabeth G Gibson, Abi Davis, Martine F Roussel, Clinton F Stewart. LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2021 May; 198(?):114025. doi: 10.1016/j.jpba.2021.114025. [PMID: 33744463]
  • Shozo Mori, Taku Aoki, Yuhki Sakuraoka, Takayuki Shimizu, Takamune Yamaguchi, Kyung-Hwa Park, Takatsugu Matsumoto, Takayuki Shiraki, Yukihiro Iso, Keiichi Kubota. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas. 2021 May; 50(5):744-750. doi: 10.1097/mpa.0000000000001826. [PMID: 34016892]
  • Franscois Runau, Ali Arshad, John D Isherwood, Jatinderpal K Sandhu, Leong L Ng, Ashley R Dennison, Donald J L Jones. Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω-3 Fatty Acid and Gemcitabine Administration: A Pilot Study. JPEN. Journal of parenteral and enteral nutrition. 2021 05; 45(4):738-750. doi: 10.1002/jpen.1952. [PMID: 32716569]
  • David D'Andrea, Surena Matin, Peter C Black, Firas G Petros, Homayoun Zargar, Colin P Dinney, Michael S Cookson, Wassim Kassouf, Marc A Dall'Era, John S McGrath, Jonathan L Wright, Andrew C Thorpe, Todd M Morgan, Jeffrey M Holzbeierlein, Trinity J Bivalacqua, Srikala S Sridhar, Scott North, Daniel A Barocas, Yair Lotan, Andrew J Stephenson, Bas W van Rhijn, Philippe E Spiess, Siamak Daneshmand, Shahrokh F Shariat. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU international. 2021 05; 127(5):528-537. doi: 10.1111/bju.15253. [PMID: 32981193]
  • Pyo June Pak, Dong Gun Lee, Ji Hyun Sung, Seung Hyun Jung, Tae-Young Han, Sung Hyo Park, Namhyun Chung. Synergistic effect of the herbal mixture C5E on gemcitabine treatment in PANC‑1 cells. Molecular medicine reports. 2021 05; 23(5):. doi: 10.3892/mmr.2021.11954. [PMID: 33760105]
  • Eleonore Coppens, Didier Desmaële, Julie Mougin, Sandrine Tusseau-Nenez, Patrick Couvreur, Simona Mura. Gemcitabine Lipid Prodrugs: The Key Role of the Lipid Moiety on the Self-Assembly into Nanoparticles. Bioconjugate chemistry. 2021 04; 32(4):782-793. doi: 10.1021/acs.bioconjchem.1c00051. [PMID: 33797231]
  • Sawsan M A El-Sheikh, Mohamed H Khairy, Eman Osama, Mohamed M M Metwally, Azza A A Galal. Nanotechnology improves the therapeutic efficacy of gemcitabine against a human hepatocellular carcinoma cell line and minimizes its in vivo side effects. Naunyn-Schmiedeberg's archives of pharmacology. 2021 04; 394(4):631-643. doi: 10.1007/s00210-020-02004-y. [PMID: 33104848]
  • Kohei Matsubara, Kai Yamasaki, Kazuki Tanimura, Kota Hira, Yuki Okuhiro, Yuko Ishii, Chika Nitani, Keiko Okada, Hiroyuki Fujisaki, Junichi Hara. [Gemcitabine and Docetaxel for the Treatment of Relapsed and Refractory Malignant Rhabdoid Tumor of Kidney and Atypical Teratoid Rhabdoid Tumor]. Gan to kagaku ryoho. Cancer & chemotherapy. 2021 Apr; 48(4):537-540. doi: NULL. [PMID: 33976041]